Obio Technology (shanghai) Corp Ltd
688238
Company Profile
Business description
Obio Technology (shanghai) Corp Ltd is a biotechnology company focusing on the field of gene therapy, focusing on the development of gene therapy vectors, gene function research, drug targets and efficacy for the basic research of gene therapy Research and other CRO services, and provide CDMO services such as process development and testing, IND-CMC pharmaceutical research, and clinical sample GMP production for the research and development of genetic drugs.
Contact
Lane 908, Ziping Road
Building 19
International Medical Park, Pudong New Area
Shanghai201321
CHNT: +86 2158585887
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
731
Stocks News & Analysis
video
What does the RBA rate cut mean for investors?
Morningstar's Chief Investment Officer for Asia-Pacific and Director of Personal Finance share their thoughts on the recent RBA rate cut.
stocks
Insights from reporting season: So far, so good
We’ve upgraded our fair value estimate for 29 companies, or 40% of those that have reported thus far.
stocks
3 cheap ASX stocks owned by top rated funds
Our analysts think these companies are undervalued and their shares appear to have the stamp of approval from highly rated managers.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
---|---|---|---|
All Ordinaries | 8,570.90 | 30.80 | -0.36% |
CAC 40 | 8,154.51 | 31.93 | 0.39% |
DAX 40 | 22,287.56 | 27.09 | -0.12% |
Dow JONES (US) | 43,428.02 | 748.63 | -1.69% |
FTSE 100 | 8,659.37 | 3.60 | -0.04% |
HKSE | 23,477.92 | 900.94 | 3.99% |
NASDAQ | 19,524.01 | 438.36 | -2.20% |
Nikkei 225 | 38,776.94 | 98.90 | 0.26% |
NZX 50 Index | 12,752.58 | 127.78 | -0.99% |
S&P 500 | 6,013.13 | 104.39 | -1.71% |
S&P/ASX 200 | 8,296.20 | 26.60 | -0.32% |
SSE Composite Index | 3,379.11 | 28.33 | 0.85% |